24 research outputs found

    Initiation of ventricular tachycardia and fibrillation.

    No full text
    <p>14 snapshots of the membrane voltage and [Ca]<sub>i</sub> in 3 cm x 3 cm tissue. Tissue paced from the left edge. White lines indicate nodal lines, which separate opposite phase of alternans. At 320 ms S2 wave hit the S1 waveback (induced by *). Then a spiral wave (i.e. ventricular tachycardia) is initiated (460-960 ms). The spiral wave spontaneously brakes up at 1040 ms. </p

    Subcellular Ca dynamics in a single cell during development of alternans.

    No full text
    <p>(A-D) Four independent simulations with the same parameters and initial conditions are shown. Each panel has the amplitude of APD alternans (top) and space-time plot of the amplitude of Ca transient alternans (bottom).</p

    Tissue paced from the end.

    No full text
    <p>Steady state APD (A) and Ca (B) alternans amplitude when PCL is changed from 300 ms to 280 ms. The leftmost 5 cell (at 0 cm) are paced in the 1D cable. </p

    APD and peak CaT during development of alternans after a change in CL.

    No full text
    <p>(A) APD (top) and peak Ca transient (bottom) vs beat number <i>n</i>. (B) The amplitude of APD (Δ<i>a</i><sub><i>n</i></sub>) and Ca transient (Δ<i>c</i><sub><i>n</i></sub>) alternans amplitude vs. beat number for five independent simulations with identical parameters and initial conditions. Differences between each simulation run are due only to the Ca cycling fluctuations present. (C) The amplitude (Δ<i>c</i><sub><i>n</i></sub>) of Ca transient alternans vs beat number <i>n</i> at the early stages of pacing. </p

    Formation of Spatially Discordant Alternans Due to Fluctuations and Diffusion of Calcium

    Get PDF
    <div><p>Spatially discordant alternans (SDA) of action potential duration (APD) is a phenomenon where different regions of cardiac tissue exhibit an alternating sequence of APD that are out-of-phase. SDA is arrhythmogenic since it can induce spatial heterogeneity of refractoriness, which can cause wavebreak and reentry. However, the underlying mechanisms for the formation of SDA are not completely understood. In this paper, we present a novel mechanism for the formation of SDA in the case where the cellular instability leading to alternans is caused by intracellular calcium (Ca) cycling, and where Ca transient and APD alternans are electromechanically concordant. In particular, we show that SDA is formed when rapidly paced cardiac tissue develops alternans over many beats due to Ca accumulation in the sarcoplasmic reticulum (SR). The mechanism presented here relies on the observation that Ca cycling fluctuations dictate Ca alternans phase since the amplitude of Ca alternans is small during the early stages of pacing. Thus, different regions of a cardiac myocyte will typically develop Ca alternans which are opposite in phase at the early stages of pacing. These subcellular patterns then gradually coarsen due to interactions with membrane voltage to form steady state SDA of voltage and Ca on the tissue scale. This mechanism for SDA is distinct from well-known mechanisms that rely on conduction velocity restitution, and a Turing-like mechanism known to apply only in the case where APD and Ca alternans are electromechanically discordant. Furthermore, we argue that this mechanism is robust, and is likely to underlie a wide range of experimentally observed patterns of SDA. </p> </div

    Subcellular Ca dynamics when a cell is paced with an AP clamp waveform.

    No full text
    <p>(A) Periodic AP clamp. (B-C) AP clamp alternating in a LSLS and SLSL sequence respectively. AP clamp is taken from a recording of a single sarcomere paced at CL= 300 ms with stable Ca cycling (<i>u</i>=1.5 ms<sup>-1</sup>). Initial conditions are chosen so that sarcomeres above (below) the 12th sarcomere start with opposite alternans phase. </p

    Steady state patterns of APD and CaT alternans in 2D tissue.

    No full text
    <p>Two independent simulations with <i>D</i><sub><i>v</i></sub>=2.5Ă—10<sup>-3</sup> cm<sup>2</sup>/ms (A-B), and <i>D</i><sub><i>v</i></sub>=6.25Ă—10<sup>-4</sup> cm<sup>2</sup>/ms (C-D). </p

    Development of SDA in a cable of 200 cells (3cm).

    No full text
    <p>The profiles of the amplitudes of APD and CaT alternans at (A) beat 110, (B) beat 140, and (C) beat 400. (D) Details of the profiles at 400 beat between 100 and 115 cells. Green lines indicate cell boundaries. Since the amplitude of APD alternans is small, it will take time to synchronize these subcellular SDA. Space-time plots of the APD alternans amplitude (E) and the CaT alternans amplitude (F).</p

    Development and synchronization of alternans within 5 coupled cells.

    No full text
    <p>The amplitude of APD alternans (top) and a space-time plot of subcellular Ca (bottom). Dashed lines indicate cell boundaries.</p

    CaMKII Phosphorylation of Na<sub>V</sub>1.5: Novel in Vitro Sites Identified by Mass Spectrometry and Reduced S516 Phosphorylation in Human Heart Failure

    No full text
    The cardiac voltage-gated sodium channel, Na<sub>V</sub>1.5, drives the upstroke of the cardiac action potential and is a critical determinant of myocyte excitability. Recently, calcium (Ca<sup>2+</sup>)/calmodulin­(CaM)-dependent protein kinase II (CaMKII) has emerged as a critical regulator of Na<sub>V</sub>1.5 function through phosphorylation of multiple residues including S516, T594, and S571, and these phosphorylation events may be important for the genesis of acquired arrhythmias, which occur in heart failure. However, phosphorylation of full-length human Na<sub>V</sub>1.5 has not been systematically analyzed and Na<sub>V</sub>1.5 phosphorylation in human heart failure is incompletely understood. In the present study, we used label-free mass spectrometry to assess phosphorylation of human Na<sub>V</sub>1.5 purified from HEK293 cells with full coverage of phosphorylatable sites and identified 23 sites that were phosphorylated by CaMKII in vitro. We confirmed phosphorylation of S516 and S571 by LC–MS/MS and found a decrease in S516 phosphorylation in human heart failure, using a novel phospho-specific antibody. This work furthers our understanding of the phosphorylation of Na<sub>V</sub>1.5 by CaMKII under normal and disease conditions, provides novel CaMKII target sites for functional validation, and provides the first phospho-proteomic map of full-length human Na<sub>V</sub>1.5
    corecore